Search the Newsreel

HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics is focusing its mRNA platform on rare diseases like cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency, utilizing its vaccine business to fund these therapeutic developments. The company expects to decide on advancing its inhaled mRNA treatment for CF (ARCT-032) into Phase …

H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9

H.C. Wainwright has reiterated its Hold rating on Arcturus Therapeutics (ARCT.US) and maintained its target price at $9. This indicates that the firm sees the stock as likely to perform in line with the broader market and does not anticipate significant price movement from …

Why High Arctic Energy Services Inc. stock is rising today

Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded Arcturus Therapeutics (ARCT) from "strong sell" to "sell," while Weiss Ratings maintained its "sell (D-)" rating. Despite these downgrades, MarketBeat's analyst consensus remains a "Moderate Buy" with an average price target of $24.25. The clinical-stage biotech company, which develops mRNA …

Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS

Arcturus Therapeutics (NASDAQ:ARCT) announced its quarterly earnings, reporting an EPS of ($0.84), beating analyst estimates by $0.16, despite revenue of $2.96 million falling short of expectations. The company provided updates on clinical trials for ARCT-810 and ARCT-032, and regained global rights to its KOSTAIVE …

Arcturus Therapeutics (ARCT) Stock Jumps As Cash Runway Reframes Pipeline Risk

Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside

Arcturus Therapeutics Holdings Inc.'s average stock price target has been reduced from $20.6 to $20.2 by 10 analysts, still suggesting a significant 232% potential upside based on its closing price on August 6. Despite the target cut, the consensus rating from 13 analysts remains …

High Arctic lifts Q2 revenue on Duvernay rentals and Team Snubbing turnaround

High Arctic Energy Services Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, Aug. 07, 2026 (GLOBE NEWSWIRE) -- High Arctic Energy Services Inc. (TSX: HWO) …

CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20

CCORF has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) but has adjusted its target price downwards to $20. This indicates a continued positive outlook on the stock, albeit with a revised valuation.

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including continued progress in the ARCT-032 Phase 2 cystic fibrosis study and completed enrollment for the ARCT-810 Phase 2 OTC deficiency study. The company regained global rights to KOSTAIVE® and …

Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view

Arcturus Therapeutics reported a narrower-than-expected loss for Q2 2026, beating EPS forecasts by 20%, but saw a significant revenue drop due to the conclusion of its CSL Seqirus collaboration. The company emphasized progress in its rare disease pipeline, including cystic fibrosis (ARCT-032) and ornithine …

Arcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary

Arcturus Therapeutics Holdings Inc. (ARCT) reported its Q2 2026 financial results, with revenue of $2.96 million and a net loss of $23.79 million, resulting in a diluted loss per share of $(0.84). This decline in revenue is attributed to KOSTAIVE transitioning to commercial stages, …

Why High Arctic Energy Services Inc. stock is skyrocketing today

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) reported a Q2 loss of $0.84 per share, surpassing the Zacks Consensus Estimate of a $1.07 loss, and beat revenue estimates with $2.96 million. Despite underperforming the S&P 500 year-to-date, the company has exceeded EPS estimates in three of the last …

Arcturus Therapeutics: Q2 Earnings Snapshot

Why (ARCT) Price Action Is Critical for Tactical Trading

The article discusses the critical price action for Arcturus Therapeutics Holdings Inc. (ARCT) for tactical trading, highlighting a near-term strong sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 394.0:1 risk-reward setup targeting a 90.6% gain versus 0.2% risk and …

Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a share - Earnings Preview

Arcturus Therapeutics Holdings Inc (ARCT) is anticipated to report a loss of 100 cents per share in its upcoming earnings. This forecast is part of an earnings preview, suggesting investors and analysts are closely watching the company's financial performance. The full article provides more …

Antarctica Ltd Revenue Breakdown – NSE:ANTGRAPHIC

High Arctic Energy Services Inc Revenue Breakdown – TSX:HWO

Arcturus Therapeutics (ARCT) to Announce Quarterly Earnings on Thursday

Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 29.3 billion …

Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Arcturus Therapeutics Holdings Inc (ARCT), detailing its volatility, financial risk, and investment risk. It highlights the company's current risk assessment score, its beta value compared to the S&P 500 index, and various financial metrics such as maximum …

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will release its second-quarter financial results for 2026 on Thursday, August 6th, after market close. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to provide …

Arcturus Therapeutics Q2 Results: Financials and update due Aug 6

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is scheduled to release its Q2 2026 financial results after market close on August 6, 2026, followed by a conference call at 4:30 p.m. ET for a corporate update. While no specific financial figures are in the pre-announcement, …

Arcturus Therapeutics Market Sentiment

This article provides an overview of market sentiment for Arcturus Therapeutics (ARCT), including analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with an average price target significantly higher than the current price, despite rising short interest. The report …

Arcturus' 4:30 p.m. webcast follows its Aug. 6 results release

Arcturus Therapeutics Holdings Inc

This article provides details on Arcturus Therapeutics Holdings Inc (ARCT), including its current stock price and market capitalization. It highlights that revenue breakdown data by business segment and region has not yet been disclosed by the company. The page also offers general information about …

Arcturus Therapeutics Holdings Inc (ARCT) Cash Flow

This article provides a detailed cash flow statement for Arcturus Therapeutics Holdings Inc (ARCT), covering quarterly and annual data from FY2012Q3 to FY2026Q1. It breaks down operating, investing, and financing cash flows, along with specific components like capital expenditures and changes in working capital. …

Arcturus Therapeutics Holdings Inc (ARCT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Arcturus Therapeutics Holdings Inc (ARCT) focusing on its dividend and stock split history. It states that the company has not distributed dividends over the past five years. Key financial data like market capitalization and recent stock performance are …

Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Arcturus Therapeutics Holdings Inc (ARCT), listing its major shareholders and institutional holdings. Key shareholders include Federated Hermes Global Investment Management Corp., ARK Investment Management LLC, and BlackRock Institutional Trust Company, N.A., alongside data on institutional shareholding trends …

Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Arcturus Therapeutics Holdings Inc. (ARCT) on NASDAQ, showing its current stock price and performance. It indicates that Arcturus Therapeutics' stock is down by 4.84% at $5.79, with delayed prices. The page also presents a lack of …